Posted by Michael Wonder on 02 Feb 2018
New treatment option for adults with ADHD: Foquest (methylphenidate controlled release capsules) now available in Canada
1 February 2018 - First and only methylphenidate product approved in Canada with a 16-hour duration of action.
Purdue Pharma (Canada) today announced the Canadian commercial availability of Foquest (methylphenidate HCl controlled-release capsules) for the treatment of ADHD in adults (≥18 years of age). This announcement follows the 6 December 2017 Health Canada Notice of Compliance for Foquest.
Foquest is the first methylphenidate product approved in Canada with a 16-hour duration of action, and also provides an onset of action within one hour.
